Current Clinical Trials
LANAIS-HF: Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in an Outpatient Setting for Heart Failure
Damon Kelsay, MD- for people 18 and up (full criteria)
- Rancho Mirage, CA
- study started September 2021
- Damon Kelsay, MD
- Currently not accepting new patients
Description
Summary
The objective of this study is to collect and bank K2-ethylenediaminetetraacetic acid (K2EDTA) plasma to evaluate the clinical utility of the Alere NT-proBNP for Alinity i system assay as an aid in the diagnosis and assessment of severity of individuals suspected or having heart failure. The assay is further indicated for the prognosis of patients with HF (heart failure hospitalization and long-term event rates at 6-months and 1-year). Device Category: B Non-Experimental/Investigational Risk Level: Non-Significant Risk (NSR) Device Class: N/AOfficial Title
CLOSED TO ENROLLMENT: LANAIS-HF: Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in an Outpatient Setting for Heart FailureKeywords
Heart FailureEligibility
for people 18 and up
Clinical Study Details
- Currently not accepting new patients
- study started September 2021
- May 20, 2025